Biomea Fusion (BMEA) Return on Capital Employed (2021 - 2026)
Biomea Fusion (BMEA) posted Return on Capital Employed of 154.16% for Q1 2026, up 15.49% sequentially from 182.43% in Q4 2025, and up 12420.0% YoY from N/an in Q1 2025.
Biomea Fusion (BMEA) Return on Capital Employed (2021 - 2026) Analysis & Trends
Biomea Fusion has reported Return on Capital Employed for 6 years, with the latest figure at 154.16% in Q1 2026.
- Quarterly Return on Capital Employed rose 12420.0% year-over-year to 154.16% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 154.16% (up 12420.0% YoY) and the FY2025 annual result came in at 143.6%, down 2178.0% from the prior year.
- Return on Capital Employed climbed to 154.16% in Q1 2026 per BMEA's latest filing, from 182.43% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 30.3% in Q1 2022 and troughed at 278.36% in Q1 2025.
- A 5-year average of 123.42% and a median of 95.17% in 2023 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2025 and 2026: Return on Capital Employed plunged 19208 bps in 2025, then surged 12420 bps in 2026.
- Over 5 years, Return on Capital Employed stood at 70.83% in 2022, then gained by 6 bps to 66.51% in 2023, then slumped by 195 bps to 196.0% in 2024, then grew by 7 bps to 182.43% in 2025, then grew by 15 bps to 154.16% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 154.16%, 182.43%, and 209.56% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | Biomea Fusion | 97.69 Mn | 97.69 Mn | - | -186.43% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -186.43% |
| Mar 31, 2026 | -154.16% |
| Dec 31, 2025 | -182.43% |
| Sep 30, 2025 | -209.56% |
| Jun 30, 2025 | -247.31% |
| Mar 31, 2025 | -278.36% |
| Dec 31, 2024 | -196.00% |
| Sep 30, 2024 | -158.09% |
| Jun 30, 2024 | -116.70% |
| Mar 31, 2024 | -86.29% |
| Dec 31, 2023 | -66.51% |
| Sep 30, 2023 | -52.15% |
| Jun 30, 2023 | -64.61% |
| Mar 31, 2023 | -95.17% |
| Dec 31, 2022 | -70.83% |
| Sep 30, 2022 | -51.20% |
| Jun 30, 2022 | -38.54% |
| Mar 31, 2022 | -30.30% |
| Dec 31, 2021 | -22.17% |
| Sep 30, 2021 | -15.30% |